Wound Management Technologies Exhibits at the American Academy of Orthopaedic Surgeons 2015 Annual Meeting

ADDISON, TX / ACCESSWIRE / March 18, 2015 / Wound Management Technologies, Inc. (OTCQB:WNDM) (“Company”), an emerging commercial stage company with its primary product, a patent-protected and FDA-cleared collagen product, CellerateRX(R), today announced that its subsidiary, Wound Care Innovations (“WCI”), will be an exhibitor at the American Academy of Orthopaedic Surgeons (“AAOS”) Annual Meeting on March 24-28, to be held at the Venetian/Sands Expo in Las Vegas, Nevada. Wound Care Innovations will be located at booth #6729.

Wound Care Innovations will feature CellerateRX(R) Surgical and the benefits of Activated Collagen(R) on surgical wounds. Dr. Blaine Farless, Medical Director of the Company’s Resorbable Orthopaedics Products (“ROP”) subsidiary, will be in attendance with the sales force and key members of the organization. Dr. Farless and the team will highlight new CellerateRX(R) surgical case studies in addition to gathering market input for the Company’s resorbable bone wax from conference attendees.

Robert Lutz, Jr., Chairman and Chief Executive Officer, commented, “We are excited to return to the American Academy of Orthopaedic Surgeons annual meeting as an exhibitor. The results from our clinical case studies featuring CellerateRX(R) Activated Collagen(R) on surgical wounds are quite impactful and we look forward to showcasing them to the largest gathering of orthopaedic surgeons. Physicians across many varying specialties continue to recognize the extraordinary benefits of CellerateRX(R) on a surgical wound as we continue to increase our presence in the operating room.”

About Wound Management Technologies

Wound Management Technologies, Inc. is an emerging commercial stage company with its primary products in the $5B worldwide advanced wound care market. Wound Management’s primary focus is the distribution of its Wound Care Innovations subsidiary’s unique, patented collagen product line, CellerateRX(R) which is FDA-cleared for all wound types except 3rd degree burns. The wound care product line is reimbursable under Medicare Part B and the surgical products are reimbursable as part of procedural billing. Wound Management has other advanced biotech products in development including a patented resorbable bone hemostat line that is in late stages of development. For more information visit www.wmgtech.com.

To download Wound Management Technologies’ investor relations app, which offers access to SEC documents, press releases, audio casts and more, please visit http://bit.ly/1zhNwnO to download on your iPhone and iPad or http://bit.ly/149PgWc for your Android mobile device.

Information about Forward-Looking Statements

The statements in the press release that relate to the Company’s expectations with regard to the future impact on the Company’s results from new products in development and any other statements not constituting historical facts are “forward-looking statements,” within the meaning of and subject to the safe harbor created by the Private Securities Litigation Reform Act of 1995. Since this information may contain statements that involve risk and uncertainties and are subject to change at any time, the Company’s actual results may differ materially from expected results. This document may contain forward-looking statements concerning the Company’s operations, current and future performance and financial condition. These items involve risks, contingencies and uncertainties such as product demand, market and customer acceptance, the effect of economic conditions, competition, pricing, the ability to consummate and integrate acquisitions, and other risks, contingencies and uncertainties detailed in the Company’s SEC filings, which could cause the Company’s actual operating results, performance or business plans or prospects to differ materially from those expressed in, or implied by these statements. The Company undertakes no obligation to revise any of these statements to reflect the future circumstances or the occurrence of unanticipated events.

Investor Contacts:

KCSA Strategic Communications
Todd Fromer / Garth Russell
+ 212-682-6300
Tfromer@kcsa.com / Grussell@kcsa.com

SOURCE: Wound Management Technologies, Inc.

ReleaseID: 426968